Background:Previous findings suggested that bevacizumab might be able to improve response rate (RR) in colorectal cancer patients with high lactic dehydrogenase (LDH) basal levels.Methods:We conducted a phase II trial to prospectively ascertain whether bevacizumab in combination with FOLFIRI could have an improved clinical activity in patients with high LDH serum levels. Primary end point of the study was RR; secondary end points were median overall survival and median progression-free survival (mPFS).Results:A total of 81 patients were enrolled. No difference in terms of ORR (39% vs 31% for low vs high LDH level stratum, P=0.78) and mPFS (14.16 vs 10.29 months, HR: 1.07, 95% CI: 0.51-2.24, P=0.83) between the strata was observed, whereas overall survival (OS) was significantly longer for patients with low LDH (24.85 vs 15.14 months, HR: 4.08, 95% CI: 1.14-14.61, P=0.0004). In a not-pre-planned exploratory analysis using different cut-off ranges for LDH, we observed RR up to 70%, with no improvement in progression-free survival or OS.Conclusions:The CENTRAL trial failed to demonstrate that high LDH levels were related to a significantly improved RR in patients receiving first-line FOLFIRI and bevacizumab. The LDH serum levels should then no further be investigated as a predictive factor in this setting.

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial / Giampieri, Riccardo; Puzzoni, Marco; Daniele, Bruno; Ferrari, Daris; Lonardi, Sara; Zaniboni, Alberto; Cavanna, Luigi; Rosati, Gerardo; Pella, Nicoletta; Zampino, Maria Giulia; Sozzi, Pietro; Germano, Domenico; Zagonel, Vittorina; Codecà, Carla; Libertini, Michela; Labianca, Roberto; Cascinu, Stefano; Scartozzi, Mario. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 117:8(2017), pp. 1099-1104. [10.1038/bjc.2017.234]

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

Cascinu, Stefano;Scartozzi, Mario
2017

Abstract

Background:Previous findings suggested that bevacizumab might be able to improve response rate (RR) in colorectal cancer patients with high lactic dehydrogenase (LDH) basal levels.Methods:We conducted a phase II trial to prospectively ascertain whether bevacizumab in combination with FOLFIRI could have an improved clinical activity in patients with high LDH serum levels. Primary end point of the study was RR; secondary end points were median overall survival and median progression-free survival (mPFS).Results:A total of 81 patients were enrolled. No difference in terms of ORR (39% vs 31% for low vs high LDH level stratum, P=0.78) and mPFS (14.16 vs 10.29 months, HR: 1.07, 95% CI: 0.51-2.24, P=0.83) between the strata was observed, whereas overall survival (OS) was significantly longer for patients with low LDH (24.85 vs 15.14 months, HR: 4.08, 95% CI: 1.14-14.61, P=0.0004). In a not-pre-planned exploratory analysis using different cut-off ranges for LDH, we observed RR up to 70%, with no improvement in progression-free survival or OS.Conclusions:The CENTRAL trial failed to demonstrate that high LDH levels were related to a significantly improved RR in patients receiving first-line FOLFIRI and bevacizumab. The LDH serum levels should then no further be investigated as a predictive factor in this setting.
117
8
1099
1104
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial / Giampieri, Riccardo; Puzzoni, Marco; Daniele, Bruno; Ferrari, Daris; Lonardi, Sara; Zaniboni, Alberto; Cavanna, Luigi; Rosati, Gerardo; Pella, Nicoletta; Zampino, Maria Giulia; Sozzi, Pietro; Germano, Domenico; Zagonel, Vittorina; Codecà, Carla; Libertini, Michela; Labianca, Roberto; Cascinu, Stefano; Scartozzi, Mario. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 117:8(2017), pp. 1099-1104. [10.1038/bjc.2017.234]
Giampieri, Riccardo; Puzzoni, Marco; Daniele, Bruno; Ferrari, Daris; Lonardi, Sara; Zaniboni, Alberto; Cavanna, Luigi; Rosati, Gerardo; Pella, Nicoletta; Zampino, Maria Giulia; Sozzi, Pietro; Germano, Domenico; Zagonel, Vittorina; Codecà, Carla; Libertini, Michela; Labianca, Roberto; Cascinu, Stefano; Scartozzi, Mario
File in questo prodotto:
File Dimensione Formato  
giampieri2017.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 775.36 kB
Formato Adobe PDF
775.36 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1157141
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 11
social impact